Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in T2DM inadequately controlled on metformin and sulfonylurea
NCT01392677Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2011
- Primary completion
- Jan 2013
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of dapagliflozin in type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Started Oct 2011; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01392677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01392677.